AG5 Andrographolide Derivative for Low-Toxicity Cytokine Storm Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cytokine storms, such as those caused by COVID-19, bacterial infections, or immunotherapy, suffer from high toxicity, limited efficacy in modulating the inflammatory response, and lack of bioavailability in the respiratory tract.
Innovation Solution
The development of the AG5 compound, a derivative of andrographolide, which can be administered parenterally or orally, effectively reduces the inflammatory response by targeting multiple cytokines and has low toxicity and high bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to inhibit inflammatory cytokines, then the inflammatory response is inhibited, but high toxicity and significant side effects occur
Solution Approach 1:
The patent employs small molecule compounds (andrographolide derivatives) instead of large monoclonal antibodies. These small molecules are metabolized and eliminated more rapidly by the body, preventing accumulation and reducing long-term toxicity. The compounds act as temporary, disposable therapeutic agents that provide acute anti-inflammatory effect without the persistent presence and associated toxicity of monoclonal antibodies.
Solution Approach 2:
The patent modifies the chemical structure of andrographolide to create derivatives with optimized pharmacokinetic and pharmacodynamic properties. By changing molecular parameters such as lipophilicity, molecular weight, and functional groups, the compounds achieve better tissue penetration, appropriate half-life, and reduced toxicity compared to both natural andrographolide and monoclonal antibodies.
2Measurement precision
If monoclonal antibodies target single cytokines, then specific inflammatory pathways are inhibited, but the cytokine storm as a whole is not addressed
Solution Approach 1:
The andrographolide derivative compounds exhibit multi-target pharmacology, simultaneously modulating multiple cytokine pathways including IL-6, IL-1β, TNF-α, and other inflammatory mediators. This broad-spectrum activity addresses the cytokine storm comprehensively rather than targeting single cytokines, while the small molecule structure allows penetration into cellular compartments where intracellular signaling occurs.
Solution Approach 2:
The patent addresses different segments of the inflammatory response through a single compound class that can act at multiple levels: upstream signaling pathways, cytokine production, and downstream inflammatory cell activation. This segmented approach to inflammation control is achieved through the compounds' ability to interact with multiple molecular targets across the inflammatory cascade.
3Reliability
If existing drugs are used to reduce inflammatory response, then inflammation is inhibited, but they lack bioavailability in the respiratory tract
Solution Approach 1:
The andrographolide derivatives are designed with optimized lipophilicity and molecular properties that enhance penetration through biological membranes including the respiratory epithelium. The compounds achieve appropriate balance between water solubility and lipid solubility, enabling both systemic administration and effective delivery to respiratory tissues where cytokine storms occur.
4Reliability
If andrographolide is used for anti-inflammatory treatment, then inflammatory response is reduced, but structural derivatives different from AG5 are employed
Solution Approach 1:
The patent identifies specific structural modifications of andrographolide that optimize therapeutic activity while ensuring consistent structure-activity relationships. The AG5 derivative represents a specifically defined chemical structure with precise stereochemistry and functional groups that provide reproducible anti-inflammatory effects, distinguishing it from other andrographolide derivatives with different molecular configurations.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
AG5 andrographolide derivative for use in the treatment of the inflammatory reaction caused by a cytokine storm, particularly produced by CoViD-19, bacteria with superantigens or by CAR-T, TIL or BiTE cell therapies.